<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819204</url>
  </required_header>
  <id_info>
    <org_study_id>117996</org_study_id>
    <nct_id>NCT04819204</nct_id>
  </id_info>
  <brief_title>Testosterone and Neurovascular Control in Humans</brief_title>
  <official_title>Exploring the Role of Testosterone on Neurovascular Control in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of these studies are to evaluate the role of testosterone on autonomic and&#xD;
      vascular function in men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sex hormones play a pivotal role in neurovascular function in humans. In recent years, great&#xD;
      strides have been made in elucidating the roles of estrogen and progesterone on autonomic and&#xD;
      vascular control in women; however, very little is known about the impact of testosterone in&#xD;
      men. Given that low testosterone levels are associated with an increased risk of&#xD;
      cardiovascular disease, reduced exercise capacity and vascular dysfunction, it is evident&#xD;
      that testosterone plays a pivotal role in autonomic and vascular function in men. Our current&#xD;
      understanding of testosterone's effects on neurovascular control are confounded by numerous&#xD;
      factors that independently alter autonomic and vascular function such as aging and chronic&#xD;
      disease (e.g. cardiovascular disease, metabolic disease). The purpose of these studies are to&#xD;
      evaluate the role of testosterone on autonomic and vascular function in young men to better&#xD;
      isolate the effects of testosterone from the aforementioned confounding factors. The outcomes&#xD;
      of these studies will provide novel information regarding the role of male sex hormones in&#xD;
      autonomic and vascular control, and further our understanding of the influence of sex&#xD;
      hormones on human physiology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle sympathetic nerve activity</measure>
    <time_frame>After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone</time_frame>
    <description>Multi-unit postganglionic muscle sympathetic nerve activity (MSNA) will be measured by inserting a unipolar tungsten microelectrode into the peroneal nerve near the fibular head of the leg. Neural signals will be amplified, filtered (bandwidth, 700-2,000 Hz), rectified, and integrated (time constant, 0.1 s) to obtain mean voltage neurograms. MSNA will be measured during both trials to evaluate the effect of testosterone on sympathetic activity directed toward the musculature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone</time_frame>
    <description>Brachial artery flow-mediated dilation (FMD). Brachial artery FMD measures will be performed non-invasively via Doppler ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forearm blood flow</measure>
    <time_frame>After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone</time_frame>
    <description>Forearm blood flow will be measured using Doppler ultrasound at baseline and during stress (e.g. exercise)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle microvascular blood flow</measure>
    <time_frame>After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone</time_frame>
    <description>Microvascular blood flow will be measured using Diffuse correlation spectroscopy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sex hormones</measure>
    <time_frame>After 7 days GnRH antagonist alone and 7 days GnRH antagonist + Testosterone</time_frame>
    <description>Serum concentrations of total testosterone, estradiol, albumin, and sex hormone binding globulin (SHBG) will be measured to document changes in hormone concentrations. Free testosterone will be calculated using total testosterone, SHBG and albumin.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GnRH antagonist alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Cetrorelix acetate (Cetrotide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH antagonist + Testosterone add-back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Cetrorelix acetate (Cetrotide) + Testosterone gel (Androgel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix Acetate</intervention_name>
    <description>GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.</description>
    <arm_group_label>GnRH antagonist + Testosterone add-back</arm_group_label>
    <arm_group_label>GnRH antagonist alone</arm_group_label>
    <other_name>Cetrotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist</description>
    <arm_group_label>GnRH antagonist + Testosterone add-back</arm_group_label>
    <other_name>Androgel 1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderately active&#xD;
&#xD;
          -  Free of chronic disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  congenital or acquired hypogonadism&#xD;
&#xD;
          -  drug/alcohol dependence&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  current smoker&#xD;
&#xD;
          -  current opioid or cannabis user&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  inability to provide written consent&#xD;
&#xD;
          -  parkinson's disease&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  testosterone use within the last year&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel K Shoemaker, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew D'Souza, MSc</last_name>
    <phone>519-661-2111</phone>
    <phone_ext>88084</phone_ext>
    <email>adsouz58@uwo.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arlene Fleischhauer, RN</last_name>
    <email>afleisc@uwo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the University of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Kevin Shoemaker</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

